Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya3301810.26442/00403660.2019.03.000136Editorial articleПередовая статьяReview ArticleNew opportunities of dual bronchodilation therapy for patients with chronic obstructive pulmonary diseaseНовые возможности двойной бронходилатационной терапии у пациентов с хронической обструктивной болезнью легкихAvdeevS NАвдеевСергей Николаевич

член-корр. РАН, д.м.н., проф., зав. каф. пульмонологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России, зав. клиническим отд. ФГБУ «НИИ пульмонологии» ФМБА России; e-mail: sergavdeev@list.ru; тел.: 8(495)708-35-76

serg_avdeev@list.ruTrushenkoN VТрушенкоНаталья Владимировна

к.м.н., н.с. ФГБУ «НИИ пульмонологии» ФМБА России, ассистент каф. пульмонологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)Pulmonology Scientific Research Institute under Federal Medical and Biological Agency of Russian FederationФГБУ «Научно-исследовательский институт пульмонологии» ФМБА России15032019913VOL 91, NO3 (2019)ТОМ 91, №3 (2019)768511042020Copyright ©; 2019, Consilium MedicumCopyright ©; 2019, ООО "Консилиум Медикум"2019Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/33018

Currently, combinations of long-acting beta2-agonists and long-acting anticholinergics are considered as the basic therapy for majority of patients with chronic obstructive pulmonary disease (COPD). These combinations have different pharmacological characteristics and delivery devices that provides different clinical effects and new opportunities for personalized treatment of COPD. Aclidinium/formoterol fixed combination differs from other dual bronchodilators by twice-daily dosing regimen, good safety profile and a specific delivery system. Recent information on clinical efficacy and safety of aclidinium/formoterol combination in COPD patients is given in this article.

В настоящее время комбинированные комбинации бронходилататоров длительного действия - длительно действующие β2-агонисты и длительно действующие антихолинергические препараты являются базисной терапией большинства пациентов с хронической обструктивной болезнью легких (ХОБЛ). Данные комбинации отличаются друг от друга по ряду фармакологических характеристик, а также по устройству доставки, что дает предпосылки для различий в клинической эффективности и расширяет возможности персонализированного подхода к терапии ХОБЛ. Комбинация аклидиния/формотерола отличается от других комбинаций двукратным режимом дозирования, высоким профилем безопасности, а также средством доставки. В настоящей статье приведены сведения о ее клинической эффективности и безопасности у пациентов с ХОБЛ.

chronic obstructive pulmonary diseasedual bronchodilation therapyaclidinium/formoterol combinationхроническая обструктивная болезнь легкихдвойная бронходилатациятерапияаклидиний/формотеролGOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Updated 2018. Available from http://www.goldcopd.org/Авдеев С.Н., Трушенко Н.В. Двойная бронходилатация - новая парадигма длительно терапии хронической обструктивной болезни легких. Практическая пульмонология. 2015;3:24-32.Ford E.S. Hospital discharges. readmissions, and ED visits for COPD or bronchiectasis among US adults: findings from the nationwide inpatient sample 2001-2012 and nationwide emergency department sample 2006-2011. Chest. 2015;147:989-98.Ingebrigtsen T.S, Marott J.L, Nordestgaard B.G, et al. Low use and adherence to maintenance medication in chronic obstructive pulmonary disease in the general population. J Gen Intern Med. 2015;30:51-9.Bender B.G. Nonadherence in chronic obstructive pulmonary disease patients: what do we know and what should we do next? Curr Opin Pulm Med. 2014;20:132-7.Cazzola M, Calzetta L, Page C.P, Rogliani P, Facciolo F, et al. Translational study searching for synergy between glycopyrronium and indacaterol. COPD. 2014;12:175-81.Сazzola M, Molimard M. The scientific rationale for combining long - acting beta-2-agonists and muscarinic antagonist in COPD. Pulm Pharmacol Ther. 2010;23:257-67.Трофимов В.И., Сорокина Л.Н. Патогенетические основы холинолитической терапии и возможные механизмы ее потенцирования под влиянием β2-адреномиметиков. Пульмонология. 2014;(2):91-9.Van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient - centred outcomes. Prim Care Respir J. 2012;21:101-8.Deas S.D, Huprikar N. Dual bronchodilatator therapy for chronic obstructive pulmonary disease: evidence for the efficacy and safety of fixed dose combination treatments in the setting of recent guideline updates. Curr Opin Pulm Med. 2018;24:130-7.Авдеев С.Н., Трушенко Н.В. Возможности фиксированной комбинации индакатерола/гликопиррония в терапии ХОБЛ: обзор современных данных. Пульмонология. 2018;28(2):224-33.D’Urzo T, Donohue J.F, Price D, Miravitlles M, Kerwin E. Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease. Expert Rev Respir Med. 2015:9(5):519-32.Wedzicha J.A, Banerji D, Chapman K.R Indacaterol-Glycopirronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374:2222-34.Lee J.H, Lee Y.K, Kim E.K, et al. Responses to inhaled long - acting beta - agonist and corticosteroid according to COPD subtype. Respir Med. 2010;104:542-9.Miravitlles M, Calle M, Soler-Cataluna J.J. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch Bronconeumol. 2012;48:86-98.Maltais F, Singh S, Donald A.C, et al. Effects of a combination of umeclidinium/ vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double - blind clinical trials. Ther Adv Respir Dis. 2014;8:169-81.Айсанов З.Р., Авдеев С.Н., Архипов В.В., Белевский А.С., Лещенко И.В., Овчаренко С.И., Шмелев Е.И., Чучалин А.Г. Национальные клинические рекомендации по диагностике и лечению ХОБЛ: алгоритм принятия клинических решений. Пульмонология. 2017;27(1):13-20.Sharafkhaneh A, Altan A.E, Colice G.L, et al. A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation. Respir Med. 2014;108:1310-20.Авдеев С.Н., Трушенко Н.В. Новые перспективы в лечении хронической обструктивной болезни легких: в фокусе - аклидиния бромид. Пульмонология. 2015;25(6):725-35.Milara J, Gabarda E, Gavalda A, et al. An assessment of the functional profile of aclidinium in human bronchi and left atria. Eur Respir J. 2011;38:859.Rogliani P, Calzetta L, Ora J, et. al. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. Eur J Pharmacol. 2015;761:383-90.Gavalda A, Ramos I, Carcasona C, et al. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. Pulmonary Pharmacology & Therapeutics. 2014;28:114-21.Lopez-Campos J.L, Calero C, Lopez-Ramirez C, et al. Patient - reported outcomes and considerations in the management of COPD: focus on aclidinium. Patient Preference and Adherence. 2015;9:95-104.Kerwin E.M, D`Urzo A.D, Gelb A.F, et al. ACCORD I study investigators. Efficacy and safety of 12-week treatment with twice - daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012;9:90-101.Jones P.W, Singh D, Bateman E.D, et al. Efficacy and safety of treatment with twice - daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012;40:830-36.Ni H, Soe Z, Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;19.9:CD010509.Verkindre C, Fukuchi Y, Flemale A, et al. Sustained 24-h efficacy of NVA237, a once - daily long - acting muscarinic antagonists, in COPD patients. Resp Med. 2010;104:1482-9.Watz H, Beeh K.M, Magnussen H, et al. Effect of aclidinium bromide on static lung function and hyperinflation in patients with moderate to severe COPD. Eur Respir J. 2013;42:4633.Campbell M, Eliraz A, Johansson G, et al. Formoterol for maintenance and as - needed treatment of chronic obstructive pulmonary disease. Respir Med. 2005;99:1511-20.Cote C, Pearle J.L, Sharafkhaneh A, Spangenthal S. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study. Pulm Pharmacol Ther. 2009;22:44-9.Derom E, Strandgården K, Schelfhout V, Borgström L, Pauwels R. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD. Respir Med. 2007;101:1931-41.D’Urzo A.D, Rennard S.I, Kerwin E.M, et al. Efficacy and safety of fixed - dose combinations of aclidinium bromide/ formoterol fumarate: the 24-week, randomized, placebo - controlled AUGMENT COPD study. Respir Res. 2014;15:123.Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). Available from: https://clinicaltrials.gov/ct2/ show/NCT01437397Singh D, Jones P.W, Bateman E.D, et al. Efficacy and safety of aclidinium bromide/ formoterol fumarate fixed - dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178.Авдеев С.Н. Схемы терапии Беродуалом при хронической обструктивной болезни легких: при развитии обострений и в стабильный период. Практическая пульмонология. 2014;3:20-5.Watz H, Troosters T, Beeh K.M, Garcia-Aymerich J, Paggiaro P, Molins E, Notari M, Zapata A, Jarreta D. Gil EG ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. Int J COPD. 2017;12:2545-58.Jones P.W, Beeh K.M, Chapman K.R, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189:250-5.Agusti A, Hedner J, Marin J.M, et al. Night - time symptoms: a forgotten dimension of COPD. Eur Respir Rev. 2011;20:183-94.Kim Y.J, Lee B.K, Jung C.Y, et al. Patient’s perception of symptoms related to morning activity in chronic obstructive pulmonary disease: the SYMBOL Study. Korean J Intern Med. 2012;27:426-35.Roche N, Chavannes N.H, Miravitlles M. COPD symptoms in the morning: impact, evaluation and management. Respir Res. 2013;14:112.Lange P, Marott J.L, Vestbo J, Nordestgaard B.G. Prevalence of night - time dyspnoea in COPD and its implications for prognosis. Eur Respir J. 2014;43:1590-8.Price D, Small M, Milligan G, et al. Impact of night - time symptoms in COPD: a real - world study in five European countries. Int J COPD. 2013;8:595-603.Miravitlles M, Chapman K.R, Chuecos F, Ribera A, Gil E.G. The efficacy of aclidinium/formoterol on lumg function and symptoms in patients with COPD categorized by symptom status: a pooled analysis. Int J COPD. 2016;11:2041-53.Waschki B, Spruit M.A, Watz H, et al. Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med. 2012;106:522-30.Demeyer H, Louvaris Z, Frei A, et al. Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial. Thorax. 2017;72:415-23.Donaire-Gonzalez D, Gimeno-Santos E, Balcells E, et al. Benefits of physical activity on COPD hospitalisation depend on intensity. Eur Respir J. 2015;46:1281-9.Waschki B, Kirsten A.M, Holz O, et al. Disease progression and changes in physical activity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192:295-306.Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all - cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140:331-42.Troosters T, van der Molen T, Polkey M, et al. Improving physical activity in COPD: towards a new paradigm. Respir Res. 2013;14:115.Demeyer H, Burtin C, Hornikx M, et al. The minimal important difference in physical activity in patients with COPD. PLoS One. 2016;11:e0154587.Vogelmeier C, Paggiaro P.L, Dorca J, Sliwinski P, Mallet M et al. Efficacy and safety of aclidinium/formrterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur Respir J. 2016;48:1030-9.Medic G, Lindner L, van der Weijden M, Karabis A. Efficacy and safety of aclidinium/formoterol versus tiotropium in COPD: results of an indirect treatment comparison. Adv Ther. 2016;33:379-99.Make B. Safety and tolerability of fixed - dose combination aclidinium bromide/formoterol fumarate: results of two 6-month studies in patients with moderate to severe COPD. Am J Respir Crit Care Med. 2014;189:A6009.Donohue J.F, Soong W, et al. Lung function and safety of aclidinium bromide/formoterol fumarate fixed - dose combination: results of a 1-year trial in patients with COPD. Respir Med. 2016;116:41-8.Jones P.W. Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease. Int J COPD. 2015;10:677-87.Kruger P, Ehrlein B, Zier M, Greguletz R. Inspiratory flow resistance of marketed dry powder inhalers (DPI). Eur Resp J. 2014;44:Suppl 58.Newman S.P, Sutton D.J, Segarra R, Lamarca R, de Miquel G. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration. 2009;78:322-8.Block K, Fyrnys B. Impact of different inhalation volumes on the aerodynamics of aclidinium bromide delivered through the Genuair® inhaler. Am J Crit Care Med. 2010;181:A4467.Magnussen H, Watz H, Zimmermann I, et al. Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD. Respir Med. 2009;103:1832-7.Chrystyn H, Niederlaender C. The Genuair inhaler: a novel, multidose dry powder inhaler. Int J Clin Pract. 2012;66(3):309-17.Marth K, Schuller E, Pohl W. Improvements in patient - reported outcomes: a prospective, non - interventional study with aclidinium bromide for treatment of COPD. Respir Med. 2015;109:616-24.Leidy N.K, Wilcox T.K, Jones P.W, et al. EXACT-PRO Study Group. Standardizing measurement of chronic obstructive pulmonary disease exacerbations: reliability and validity of a patient - reported diary. Am J Resp Crit Care Med. 2011;183:323-9.van der Palen J, Ginko T, Kroker A. Et al. Preference, satisfaction and errors with two dry powder inhalers in patients with COPD. Expert Opin Drug Deliv. 2013;10:1023-31.